Literature DB >> 26516790

Understanding the structural mechanisms of antibiotic resistance sets the platform for new discovery.

Stephanie M Reeve1, Michael N Lombardo1, Amy C Anderson1.   

Abstract

Understanding the structural basis of antibacterial resistance may enable rational design principles that avoid and subvert that resistance, thus leading to the discovery of more effective antibiotics. In this review, we explore the use of crystal structures to guide new discovery of antibiotics that are effective against resistant organisms. Structures of efflux pumps bound to substrates and inhibitors have aided the design of compounds with lower affinity for the pump or inhibitors that more effectively block the pump. Structures of β-lactamase enzymes have revealed the mechanisms of action toward key carbapenems and structures of gyrase have aided the design of compounds that are less susceptible to point mutations.

Entities:  

Keywords:  crystal structures; efflux pump; gyrase; β-lactamase

Mesh:

Substances:

Year:  2015        PMID: 26516790      PMCID: PMC4944398          DOI: 10.2217/fmb.15.78

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  23 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

Review 2.  Winning the arms race by improving drug discovery against mutating targets.

Authors:  Amy C Anderson
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

3.  New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition.

Authors:  Dustin T King; Liam J Worrall; Robert Gruninger; Natalie C J Strynadka
Journal:  J Am Chem Soc       Date:  2012-07-05       Impact factor: 15.419

Review 4.  Recent developments in carbapenems.

Authors:  Giovanni Bonfiglio; Giovanni Russo; Giuseppe Nicoletti
Journal:  Expert Opin Investig Drugs       Date:  2002-04       Impact factor: 6.206

5.  Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance.

Authors:  Alexandre Wohlkonig; Pan F Chan; Andrew P Fosberry; Paul Homes; Jianzhong Huang; Michael Kranz; Vaughan R Leydon; Timothy J Miles; Neil D Pearson; Rajika L Perera; Anthony J Shillings; Michael N Gwynn; Benjamin D Bax
Journal:  Nat Struct Mol Biol       Date:  2010-08-29       Impact factor: 15.369

6.  Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Authors:  Wei-Sheng Huang; Chester A Metcalf; Raji Sundaramoorthi; Yihan Wang; Dong Zou; R Mathew Thomas; Xiaotian Zhu; Lisi Cai; David Wen; Shuangying Liu; Jan Romero; Jiwei Qi; Ingrid Chen; Geetha Banda; Scott P Lentini; Sasmita Das; Qihong Xu; Jeff Keats; Frank Wang; Scott Wardwell; Yaoyu Ning; Joseph T Snodgrass; Marc I Broudy; Karin Russian; Tianjun Zhou; Lois Commodore; Narayana I Narasimhan; Qurish K Mohemmad; John Iuliucci; Victor M Rivera; David C Dalgarno; Tomi K Sawyer; Tim Clackson; William C Shakespeare
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

7.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 8.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

9.  Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations.

Authors:  Attilio V Vargiu; Hiroshi Nikaido
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-21       Impact factor: 11.205

Review 10.  Mechanisms of RND multidrug efflux pumps.

Authors:  Hiroshi Nikaido; Yumiko Takatsuka
Journal:  Biochim Biophys Acta       Date:  2008-11-03
View more
  1 in total

1.  An interpretable machine learning approach to identify mechanism of action of antibiotics.

Authors:  Mihir Mongia; Mustafa Guler; Hosein Mohimani
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.